CALISTA KU: Open Payments
NPI 1982122750 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$469 in 12 payments from 8 companies in 2025. Trend: 2023 $14 · 2024 $217 · 2025 $469
Food & beverage: $439Long term medical supply or device loan: $30
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $165 |
| Dexcom, Inc. | 2 | $117 |
| Abbott Laboratories | 2 | $53 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $35 |
| Edwards Lifesciences Corporation | 1 | $29 |
| Amgen Inc. | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
Products named: Ozempic, Dexcom G6 Transmitter, Kerendia, FREESTYLE INSULINX, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVENITY, t:slim X2 Insulin Pump with Control-IQ, FREESTYLE LIBRE 3.
Industry payments across WA — which companies pay providers there.
